Ter-cell, A New Target for Hepatocellular Carcinoma Therapy

Chembiochem. 2018 Nov 2;19(21):2254-2256. doi: 10.1002/cbic.201800410. Epub 2018 Oct 12.

Abstract

Hepatocellular carcinoma (HCC), a malignancy of the liver, has become the second most lethal cause of cancer death globally. Recently, scientists discovered that a splenic erythroblast-like cell induced by the primary tumor, termed Ter-cell, promoted HCC progression and metastasis. These findings shed light on the inhibition of Ter-cell or artemin that can serve as a new therapeutic target for HCC.

Keywords: antitumor agents; artemin; cancer; hepatocellular carcinoma; therapeutic targets.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Hepatocellular / drug therapy*
  • Carcinoma, Hepatocellular / metabolism
  • Carcinoma, Hepatocellular / pathology
  • Disease Progression
  • Drug Discovery
  • Erythroblasts / drug effects*
  • Erythroblasts / metabolism
  • Erythroblasts / pathology
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / metabolism
  • Liver Neoplasms / pathology
  • Molecular Targeted Therapy
  • Neoplasm Metastasis / pathology
  • Neoplasm Metastasis / prevention & control
  • Nerve Tissue Proteins / antagonists & inhibitors*
  • Nerve Tissue Proteins / metabolism

Substances

  • ARTN protein, human
  • Antineoplastic Agents
  • Nerve Tissue Proteins